“…These data support the further use and development of noradrenergic agents for the treatment of PTSD, and are in strong accordance with the demonstrated efficacy of prazosin in both preclinical models (Olson et al , 2011) and PTSD patient populations (Raskind et al , 2003) (Krystal and Neumeister, 2009). Finally, excessive alcohol exposure and dependence itself may contribute to dysregulated signaling in the PFC (George et al , 2012; Kim et al , 2014), leading to the development or exacerbation of PTSD-associated symptoms in rodents (Holmes et al , 2012), consistent with the human literature (Tipps et al , 2014; Perrin et al , 2014). …”